Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (39) 39
oncology (29) 29
female (28) 28
middle aged (28) 28
head and neck neoplasms - drug therapy (27) 27
male (26) 26
chemotherapy (23) 23
carcinoma, squamous cell - drug therapy (22) 22
aged (21) 21
antineoplastic combined chemotherapy protocols - therapeutic use (21) 21
cancer (21) 21
head and neck neoplasms - radiotherapy (20) 20
carcinoma, squamous cell - radiotherapy (18) 18
combined modality therapy (18) 18
radiotherapy (18) 18
cisplatin - administration & dosage (16) 16
adult (14) 14
fluorouracil - administration & dosage (14) 14
head and neck cancer (14) 14
squamous cell carcinoma (12) 12
head and neck neoplasms - therapy (11) 11
index medicus (11) 11
neoplasm staging (10) 10
treatment outcome (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
chemoradiotherapy (9) 9
head and neck neoplasms - pathology (9) 9
radiation-therapy (9) 9
carcinoma, squamous cell - pathology (8) 8
squamous-cell carcinoma (8) 8
carcinoma, squamous cell - therapy (7) 7
cisplatin (7) 7
radiotherapy dosage (7) 7
survival analysis (7) 7
carcinoma, squamous cell - mortality (6) 6
care and treatment (6) 6
chemotherapy, adjuvant (6) 6
drug administration schedule (6) 6
head and neck neoplasms - mortality (6) 6
neoplasm recurrence, local - drug therapy (6) 6
radiation (6) 6
randomized trial (6) 6
antineoplastic agents - therapeutic use (5) 5
cetuximab (5) 5
head and neck (5) 5
hematology, oncology and palliative medicine (5) 5
remission induction (5) 5
survival (5) 5
therapy (5) 5
aged, 80 and over (4) 4
cancer-treatment (4) 4
clinical trials (4) 4
deoxycytidine - analogs & derivatives (4) 4
disease progression (4) 4
fluorouracil (4) 4
fluorouracil - therapeutic use (4) 4
gemcitabine (4) 4
head and neck carcinoma (4) 4
induction chemotherapy (4) 4
medicine, general & internal (4) 4
neck (4) 4
platinum (4) 4
prognosis (4) 4
radiotherapy, adjuvant (4) 4
survival rate (4) 4
thrombocytopenia - chemically induced (4) 4
trial (4) 4
5-fluorouracil (3) 3
abridged index medicus (3) 3
accelerated radiotherapy (3) 3
anemia - chemically induced (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
breast cancer (3) 3
carcinoma (3) 3
carcinoma, squamous cell - secondary (3) 3
chemo-radiotherapy (3) 3
cisplatin - therapeutic use (3) 3
deoxycytidine - administration & dosage (3) 3
disease-free survival (3) 3
irradiation (3) 3
larynx (3) 3
local-control (3) 3
locally advanced head (3) 3
management (3) 3
medical research (3) 3
oncology group rtog (3) 3
organ preservation (3) 3
otorhinolaryngology (3) 3
patients (3) 3
radiation therapy (3) 3
radiation-sensitizing agents - therapeutic use (3) 3
radiology, nuclear medicine & medical imaging (3) 3
radiotherapy - adverse effects (3) 3
randomization (3) 3
randomized clinical trial (3) 3
randomized controlled trials as topic (3) 3
recurrent (3) 3
safety (3) 3
skin (3) 3
skin toxicity (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Induction chemotherapy for squamous cell head and neck cancer: A neverending story?
by Benasso, Marco
Oral Oncology, ISSN 1368-8375, 2013, Volume 49, Issue 8, pp. 747 - 752
Summary Induction chemotherapy prior to planned definitive local therapy for head and neck squamous cell carcinoma has been studied for at least three decades... 
Otolaryngology | Hematology, Oncology and Palliative Medicine | Neo-adjuvant chemotherapy | Sequential | Platinum | Combined treatments | Larynx preservation | Taxanes | Cetuximab | RANDOMIZED-TRIAL | ADVANCED LARYNGEAL-CANCER | RADIATION-THERAPY | PHASE-III TRIAL | ALTERNATING CHEMOTHERAPY | ORGAN PRESERVATION | CISPLATIN | ONCOLOGY | DENTISTRY, ORAL SURGERY & MEDICINE | LOCALLY ADVANCED HEAD | CARCINOMA | CONCURRENT CHEMORADIOTHERAPY | Head and Neck Neoplasms - radiotherapy | Carcinoma, Squamous Cell - drug therapy | Humans | Head and Neck Neoplasms - drug therapy | Carcinoma, Squamous Cell - surgery | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Carcinoma, Squamous Cell - radiotherapy | Head and Neck Neoplasms - surgery | Chemotherapy | Squamous cell carcinoma | Nuclear radiation | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck The following oncologists partcipated in this randomized study: Paolo Bruzzi, M.D., Isabella Ricci, M.D., Katia Donato, M.D., Franca Foppiano, Ph.D. (Istituto Nazionale per la Ricerca sul Cancro, Genova); Alida Santelli, M.D., Filippo Borasi, M.D. (Divisione of Otorinolaringoiatria–Ospedale San Martino, Genova); Enzo Mora, M.D., Marco Barbieri, M.D. (Clinica Otorinolaringoiatrica-Universita, Genova); Corrado Marziano, M.D., Renato Chiarlone, M.D., Fulvio Brema, M.D. (Ospedale S. Paolo, Savona); Giovanni Ricci, M.D., Andrea Grimaldi, M.D., Monica Cavallari, M.D. (Ospedale Galliera, Genova); Giammauro Numico, M.D. (Ospedale S. Croce e Carle, Cuneo, Italy)
by Corvò, Renzo and Benasso, Marco and Sanguineti, Giuseppe and Lionetto, Rita and Bacigalupo, Almalina and Margarino, Giovanni and Pallestrini, Eugenio and Merlano, Marco and Vitale, Vito and Rosso, Riccardo
Cancer, ISSN 0008-543X, 12/2001, Volume 92, Issue 11, p. 2856
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
by Vermorken, Jan B and Mesia, Ricard and Rivera, Fernando and Remenar, Eva and Kawecki, Andrzej and Rottey, Sylvie and Erfan, Jozsef and Zabolotnyy, Dmytro and Kienzer, Heinz-Roland and Cupissol, Didier and Peyrade, Frederic and Benasso, Marco and Vynnychenko, Ihor and De Raucourt, Dominique and Bokemeyer, Carsten and Schueler, Armin and Amellal, Nadia and Hitt, Ricardo
The New England Journal of Medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 11, pp. 1116 - 1127
This randomized trial of the treatment of advanced head and neck cancer tested the efficacy of adding cetuximab, an antibody against the epidermal growth... 
GROWTH-FACTOR RECEPTOR | SINGLE-AGENT | MEDICINE, GENERAL & INTERNAL | ONCOLOGY-GROUP | CISPLATIN | RECURRENT | COPY NUMBER | SQUAMOUS-CELL CARCINOMA | PHASE-II MULTICENTER | FLUOROURACIL | ANTIBODY CETUXIMAB | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Cisplatin - administration & dosage | Antibodies, Monoclonal, Humanized | Carcinoma, Squamous Cell - mortality | Fluorouracil - administration & dosage | Female | Cetuximab | Neutropenia - chemically induced | Head and Neck Neoplasms - drug therapy | Kaplan-Meier Estimate | Anemia - chemically induced | Carboplatin - administration & dosage | Thrombocytopenia - chemically induced | Disease Progression | Carcinoma, Squamous Cell - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Squamous Cell - secondary | Aged | Head and Neck Neoplasms - mortality | Drug therapy | Chemotherapy | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
by Burtness, Barbara and Harrington, Kevin J and Harrington, Kevin and Greil, Richard and Soulières, Denis and Tahara, Makoto and de Castro, Gilberto and Psyrri, Amanda and Basté, Neus and Neupane, Prakash and Bratland, Åse and Bratland, Aase and Fuereder, Thorsten and Hughes, Brett G M and Hughes, Brett and Mesía, Ricard and Ngamphaiboon, Nuttapong and Rordorf, Tamara and Wan Ishak, Wan Zamaniah and Hong, Ruey-Long and González Mendoza, René and Roy, Ananya and Zhang, Yayan and Gumuscu, Burak and Cheng, Jonathan D and Jin, Fan and Rischin, Danny and Lerzo, Guillermo and Tatangelo, Marcelo and Varela, Mirta and Zarba, Juan Jose and Boyer, Michael and Gan, Hui and Gao, Bo and Mallesara, Girish and Taylor, Anne and Burian, Martin and Barrios, Carlos Henrique and de Castro Junior, Dalvaro Oliveira and Castro, Gilberto and Franke, Fabio Andre and Girotto, Gustavo and Lima, Iane Pinto Figueiredo and Nicolau, Ulisses Ribaldo and Pinto, Gustavo Dix Junqueira and Santos, Lucas and Victorino, Ana-Paula and Chua, Neil and Couture, Felix and Gregg, Richard and Hansen, Aaron and Hilton, John and McCarthy, Joy and Soulieres, Denis and Ascui, Rodrigo and Gonzalez, Pablo and Villanueva, Luis and Torregroza, Marco and Zambrano, Angela and Holeckova, Petra and Kral, Zdenek and Melichar, Bohuslav and Prausova, Jana and Vosmik, Milan and Andersen, Maria and Gyldenkerne, Niels and Jurgens, Hannes and Putnik, Kadri and Reinikainen, Petri and Gruenwald, Viktor and Laban, Simon and Aravantinos, Gerasimos and Boukovinas, Ioannis and Georgoulias, Vassilis and Kwong, Dora and Al-Farhat, Yousuf and Csoszi, Tibor and Erfan, Jozsef and Horvai, Geza and Landherr, Laszlo and Remenar, Eva and Ruzsa, Agnes and Szota, Judit and Billan, Salem and Gluck, Iris and Gutfeld, Orit and Popovtzer, Aron and Benasso, Marco and Bui, Simona and Ferrari, Vittorio and Licitra, Lisa and Nole, Franco and Fujii, Takashi and Fujimoto, Yasushi and Hanai, Nobuhiro and Hara, Hiroki and Matsumoto, Koji and Mitsugi, Kenji and Monden, Nobuya and Nakayama, Masahiro and ...
The Lancet, ISSN 0140-6736, 11/2019, Volume 394, Issue 10212, pp. 1915 - 1928
Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved... 
Chemotherapy | Squamous cell carcinoma | Metastasis | Analysis | Cancer | Medical research | 5-Fluorouracil | Mortality | Oncology | Survival | Metastases | Population (statistical) | Pembrolizumab | Hypotheses | Randomization | Motivation | Platinum | Cell death | PD-L1 protein | Population | Head and neck cancer | Ligands | Larynx | Safety | Apoptosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
by Cohen, Ezra E W and Cohen, Ezra and Soulières, Denis and Le Tourneau, Christophe and Dinis, Jose and Dinis, José and Licitra, Lisa and Ahn, Myung-Ju and Soria, Ainara and Machiels, Jean-Pascal and Mach, Nicolas and Mehra, Ranee and Burtness, Barbara Ann and Burtness, Barbara and Zhang, Pingye and Cheng, Jonathan and Swaby, Ramona F and Harrington, Kevin and Harrington, Kevin J and Acosta-Rivera, Mirelis and Adkins, Douglas R and Aghmesheh, Morteza and Airoldi, Mario and Aleknavicius, Eduardas and Al-Farhat, Yousuf and Algazi, Alain P and Almokadem, Salah and Alyasova, Anna and Bauman, Jessica R and Benasso, Marco and Berrocal, Alfonso and Bray, Victoria and Caponigro, Francesco and Castro, Ana and Cescon, Terrence P and Chan, Kelvin and Chaudhry, Arvind and Chauffert, Bruno and Csoszi, Tibor and De Boer, J.P and Delord, Jean-Pierre and Dietz, Andreas and Dupuis, Charlotte and Digue, Laurence and Erfan, Jozsef and Escobar Alvarez, Yolanda and Evans, Mererid and Fidler, Mary Jo and Forster, Martin David and Friesland, Signe and Ganti, Apar K and Geoffrois, Lionnel and Grant, Cliona and Gruenwald, Viktor and Hoffmann, Thomas and Horvai, Geza and Inciura, Arturas and Jang, Raymond and Jankowska, Petra and Jimeno, Antonio and Joseph, Mano and Juarez Ramiro, Alejandro and Karaszewska, Boguslawa and Kawecki, Andrzej and Keilholz, Ulrich and Keller, Ulrich and Kim, Sung-Bae and Kocsis, Judit and Kotecki, Nuria and Kozloff, Mark F and Lambea, Julio and Landherr, Laszlo and Lantsukhay, Yuri and Lazarev, Sergey Alexandrovich and Lee, Lip Way and Lifirenko, Igor Dmitrievich and Martincic, Danko and Matorin, Oleg Vladmirovhich and McGrath, Margaret and Misiukiewicz, Krzysztof and Morris, John C and Mufazalov, Fagim Fanisovich and Niu, Jiaxin and Pamoorthy Srinivasan, Devraj and Perez Segura, Pedro and Rauch, Daniel and Ribeiro, Maria Leonor and Rodriguez, Cristina and Rolland, Frederic and Russo, Antonio and Ruzsa, Agnes and Sanches, Frederico and Shin, Sang-Won and Shtiveland, Mikhail and Soulieres, Denis and Specenier, Pol and Szekanecz, Eva and Szota, Judit and van Herpen, Carla M.L and Velez-Cortes, Hector A and ... and Keynote-040 Investigators and KEYNOTE-040 investigators
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10167, pp. 156 - 167
There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour... 
CRITERIA | TRIAL | MEDICINE, GENERAL & INTERNAL | NIVOLUMAB | CANCER | CHEMOTHERAPY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Docetaxel - adverse effects | Humans | Middle Aged | Squamous Cell Carcinoma of Head and Neck - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Cetuximab - therapeutic use | Cetuximab - adverse effects | Docetaxel - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Squamous Cell Carcinoma of Head and Neck - drug therapy | Female | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Head and Neck Neoplasms - drug therapy | Kaplan-Meier Estimate | Disease Progression | Head and Neck Neoplasms - pathology | Methotrexate - adverse effects | Squamous Cell Carcinoma of Head and Neck - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cetuximab - administration & dosage | Methotrexate - administration & dosage | Aged | Methotrexate | Squamous cell carcinoma | Metastasis | Therapy | Toxicity | Perforation | Clinical trials | Oncology | Cancer therapies | Metastases | Skin cancer | Anticancer properties | Pembrolizumab | Randomization | Motivation | Platinum | Neck | Safety | Medical treatment | Fatigue | Hypothyroidism | Survival | Patients | Chemotherapy | Interactive systems | Large intestine | Head and neck cancer | Ligands | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Impact of treatment expertise on the outcome of patients with head and neck cancer treated within 6 randomized trials
by Bossi, Paolo and Miceli, Rosalba and Benasso, Marco and Corvò, Renzo and Bacigalupo, Andrea and Sanguineti, Giuseppe and Fallai, Carlo and Merlano, Marlo C and Infante, Gabriele and Dani, Carla and Di Giannantonio, Valerio and Licitra, Lisa
Head & Neck, ISSN 1043-3074, 12/2018, Volume 40, Issue 12, pp. 2648 - 2656
Background We evaluated the impact of center expertise, in terms of number of patients treated, on the overall survival (OS) and progression‐free survival... 
treatment expertise | referral centers | HNCC | survival | SURGERY | MANAGEMENT | INSTITUTION | FACILITIES | INTENSITY | IMPROVED SURVIVAL | ALTERNATING CHEMOTHERAPY | HOSPITAL VOLUME | OTORHINOLARYNGOLOGY | SQUAMOUS-CELL CARCINOMA | LOCALLY ADVANCED HEAD | RADIOTHERAPY | Squamous cell carcinoma | Cell survival | Clinical trials | Data processing | Head and neck cancer | Radiation therapy | Neck | Patients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Individual patient data meta-analysis of the IMPACT of treatment site on the outcome of head and neck cancer patients treated within 6 randomized trials
by Bossi, Paolo and Miceli, Rosalba and Benasso, Marco and Corvò, Renzo and Bacigalupo, Almalina and Sanguineti, Giuseppe and Fallai, Carlo and Merlano, Marco Carlo and Infante, Gabriele and Dani, Carla and Licitra, Lisa F
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 6022 - 6022
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text The effects on pain and activity of daily living caused by crusted exudation in patients with head and neck cancer treated with cetuximab and radiotherapy
by Russi, Elvio G and Russi, Elvio G and Merlano, Marco C and Merlano, Marco C and Numico, Gianmauro and Numico, Gianmauro and Corvò, Renzo and Corvò, Renzo and Benasso, Marco and Benasso, Marco and Vigna-Taglianti, Riccardo and Vigna-Taglianti, Riccardo and Melano, Antonella and Melano, Antonella and Denaro, Nerina and Denaro, Nerina and Pergolizzi, Stefano and Pergolizzi, Stefano and Colantonio, Ida and Colantonio, Ida and Lucio, Francesco and Lucio, Francesco and Brizio, Rodolfo and Brizio, Rodolfo and Ricardi, Umberto and Ricardi, Umberto
Supportive Care in Cancer, ISSN 0941-4355, 9/2012, Volume 20, Issue 9, pp. 2141 - 2147
To date, the specific role of “in-field” crusting exudation on pain and on activity of daily living (ADL) in head and neck cancer (HNSCC) patients undergoing... 
Pain Medicine | Radiodermatitis | Rehabilitation Medicine | Nursing | Medicine & Public Health | Skin toxicity | Oncology | Head and neck cancer | Nursing Management/Nursing Research | Chemoradiotherapy and cetuximab | PLUS CETUXIMAB | DERMATOLOGICAL TOXICITIES | RADIATION | THERAPY | ONCOLOGY | INFLAMMATION | HEALTH CARE SCIENCES & SERVICES | SQUAMOUS-CELL CARCINOMA | ALTERNATING RADIOTHERAPY | REHABILITATION | QUALITY-OF-LIFE | SKIN | CONCURRENT CETUXIMAB | Radiodermatitis - pathology | Severity of Illness Index | Humans | Head and Neck Neoplasms - drug therapy | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Activities of Daily Living | Antibodies, Monoclonal, Humanized | Head and Neck Neoplasms - radiotherapy | Pain - physiopathology | Pain - etiology | Cetuximab | Radiodermatitis - physiopathology | Exudates and Transudates | Chemotherapy | Pain | Head & neck cancer | Radiation therapy | Dermatitis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus
by Russi, Elvio G and Moretto, Francesco and Rampino, Monica and Benasso, Marco and Bacigalupo, Almalina and De Sanctis, Vitaliana and Numico, Gianmauro and Bossi, Paolo and Buglione, Michela and Lombardo, Antonino and Airoldi, Mario and Merlano, Marco C and Licitra, Lisa and Denaro, Nerina and Pergolizzi, Stefano and Pinto, Carmine and Bensadoun, Renè- Jean and Girolomoni, Giampiero and Langendijk, Johannes A
Critical Reviews in Oncology and Hematology, ISSN 1040-8428, 2015, Volume 96, Issue 1, pp. 167 - 182
Highlights • Baseline assessment (successively, during CRT, at least weekly) and preventive recommendations. • Topical steroidal agents. • Dressings and... 
Hematology, Oncology and Palliative Medicine | Chemotherapy | Skin toxicity | EGFRi | Head and neck cancer | Biodermatitis | Radiotherapy | Cetuximab | ACUTE RADIATION DERMATITIS | INTENSITY-MODULATED RADIOTHERAPY | RANDOMIZED CONTROLLED-TRIAL | CLINICAL-PRACTICE GUIDELINES | ONCOLOGY GROUP RTOG | PATIENTS RECEIVING RADIOTHERAPY | COLLAGEN VASCULAR-DISEASES | ONCOLOGY | INDUCED MOIST DESQUAMATION | SQUAMOUS-CELL CARCINOMA | III DOUBLE-BLIND | HEMATOLOGY | Dermatitis - etiology | Dermatitis - therapy | Chemoradiotherapy - adverse effects | Humans | Risk Factors | Head and Neck Neoplasms - therapy | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Pruritus - etiology | Consensus | Cetuximab - adverse effects | Cancer patients | Care and treatment | Skin | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. The viewpoint of the medical oncologist
by Benasso, Marco
Tumori, ISSN 0300-8916, 07/2008, Volume 94, Issue 4, p. suppl 26
Humans | Endpoint Determination - methods | Antineoplastic Agents - therapeutic use | Evidence-Based Medicine | Remission Induction | Randomized Controlled Trials as Topic | Radiation-Sensitizing Agents - therapeutic use | Disease-Free Survival | Medical Oncology | Taxoids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Chemotherapy, Adjuvant | Radiotherapy, Adjuvant | Endpoint Determination - trends
Journal Article
Details down arrow
11. Il punto di vista dell'oncologo medico
by Benasso, Marco
Tumori, ISSN 0300-8916, 07/2008, Volume 94, Issue 4, pp. 26 - 29
Journal Article
Details down arrow
12. Full Text Gemcitabine‐Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta‐Analysis
by Vanderveken, Olivier M and Szturz, Petr and Specenier, Pol and Merlano, Marco C and Benasso, Marco and Van Gestel, Dirk and Wouters, Kristien and Van Laer, Carl and Van den Weyngaert, Danielle and Peeters, Marc and Vermorken, Jan
The Oncologist, ISSN 1083-7159, 01/2016, Volume 21, Issue 1, pp. 59 - 71
Background. Platinum‐based concurrent chemoradiation (CCRT) improves locoregional control and overall survival of locoregionally advanced (LA) squamous cell... 
Chemotherapy | Gemcitabine | Toxicity | Radiation | Head and neck cancer | Oncology | Radiotherapy | Concomitant chemoradiotherapy | Neoplasms | REDUCE SWALLOWING DYSFUNCTION | INDUCTION CHEMOTHERAPY | CONCURRENT RADIOTHERAPY | FOLLOW-UP | OF-THE-ART | RADIATION-THERAPY | CISPLATIN | III RANDOMIZED-TRIAL | PHASE-I TRIAL | SQUAMOUS-CELL CARCINOMA | Neoplasm Recurrence, Local - radiotherapy | Carcinoma, Squamous Cell - pathology | Humans | Head and Neck Neoplasms - drug therapy | Neoplasm Recurrence, Local - drug therapy | Carcinoma, Squamous Cell - radiotherapy | Head and Neck Neoplasms - pathology | Neoplasm Recurrence, Local - pathology | Radiation-Sensitizing Agents - therapeutic use | Head and Neck Neoplasms - radiotherapy | Deoxycytidine - therapeutic use | Squamous Cell Carcinoma of Head and Neck | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Deoxycytidine - analogs & derivatives | Radiotherapy, Intensity-Modulated | Head and Neck Cancers
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Selection of systemic therapy in patients with locally advanced and recurrent/metastatic head and neck cancer: RAND-based expert opinion by an Italian multidisciplinary panel
by Benasso, Marco and Bonomo, Pierluigi and Buglione, Michela and Ghi, Maria Grazia and Licitra, Lisa and Magrini, Stefano Maria and Merlano, Marco Carlo and Presutti, Livio and Ronzino, Graziana and Ferrari, Daris
Tumori, 08/2019, p. 300891619868289
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease often presenting at an already advanced stage. Cisplatin chemoradiotherapy is the... 
Journal Article
Details down arrow
14. Full Text Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies
by Lambertini, Matteo and Ceppi, Marcello and Cognetti, Francesco and Cavazzini, Giovanna and De Laurentiis, Michele and De Placido, Sabino and Michelotti, Andrea and Bisagni, Giancarlo and Durando, Antonio and Valle, Enrichetta and Scotto, Tiziana and De Censi, Andrea and Turletti, Anna and Benasso, Marco and Barni, Sandro and Montemurro, Filippo and Puglisi, Fabio and Levaggi, Alessia and Giraudi, Sara and Bighin, Claudia and Bruzzi, Paolo and Del Mastro, Lucia and GIM Study Grp and MIG Study Grp and MIG and GIM study groups
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 71, pp. 34 - 42
Abstract Background No evidence exists to recommend a specific chemotherapy regimen in young breast cancer patients. We performed a pooled analysis of two... 
Hematology, Oncology and Palliative Medicine | Treatment-induced amenorrhoea | Premenopausal patients | Breast cancer | Dose-dense chemotherapy | AMENORRHEA | TRIALS | METAANALYSIS | MANAGEMENT | CONSENSUS | ONCOLOGY | RECOMMENDATIONS | ANTHRACYCLINE | OUTCOMES | YOUNG-WOMEN | FERTILITY CONCERNS | Premenopause | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Fluorouracil - therapeutic use | Fluorouracil - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Epirubicin - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Amenorrhea - chemically induced | Epirubicin - adverse effects | Care and treatment | Cancer patients | Analysis | Oncology, Experimental | Menopause | Adjuvant treatment | Clinical trials | Research | Epidemiology | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights